(Date:5/16/2008)...nce-promising drug formerly approved as a second l...a, enhanced the effectiveness of hormonal therapy ...breast cancer, according to a Phase II clinical tr...M. D. Anderson Cancer Center. , These findings a...dy for Iressa in breast cancer, as well as for the...
(Date:5/16/2008)...USNewswire/ -- Behavioral healthcare,systems are p...the millions,of Americans of all ages who experien...ear, according to the latest annual survey from th...ms (NAPHS) released today., The 2007 NAPHS Annual...healthcare delivery. One chapter provides a trend ...
(Date:5/16/2008)...of Nomura Code Securities Limited as ... May 16 /PRNewswire-FirstCall/ -- Medicsight PLC, ...x: MGT ) (the "Company"), and an,industry leader ...D) and,image analysis software which assists in th...announced the appointment of NM Rothschild & Sons ...
(Date:5/16/2008)...wire/ -- Tao Formulations announces the,official l...t the Internal,Medicine 2008 conference in Washing...ion of years of research to develop a safe, all-na...r relieving menopausal symptoms., Company founder...ician,and gynecologist, founded Tao Formulations ...
Breaking Medicine News(10 mins):Health News:Iressa shows promise for treatment of metastatic breast cancer when combined with hormonal therapy 2Health News:Iressa shows promise for treatment of metastatic breast cancer when combined with hormonal therapy 3Health News:New NAPHS Annual Survey Tracks Behavioral Treatment Trends 2Health News:Medicsight Announces Appointment of NM Rothschild & Sons Limited as Corporate Adviser 2Health News:Medicsight Announces Appointment of NM Rothschild & Sons Limited as Corporate Adviser 3Health News:Tao Formulations Announces the Official Launch of Tao Harmony - Menopause Relief Formula 2(Date:5/15/2008)...ay 15 /- Eisai Corporation of North,A...al data abstracts about,compounds in the company,s...cal oncology research have been accepted for prese... Society of Clinical Oncology (ASCO),taking place...variety of abstracts on Eisai marketed products an...
(Date:5/15/2008)...ical Data from Prostate, Colorectal and Ovarian ...to Hold Investor Event on Sun., June 1 with Oncolo... /- Poniard,Pharmaceuticals...ny focused,on oncology, today announced that the C...s of picoplatin, in various tumor types and combin...
(Date:5/15/2008)...5 /- Schering-Plough,Corpor...ence and treatment of,chronic hepatitis C virus (H...ral clinical studies with PEGINTRON(TM) (peginterf...ination therapy, as well as boceprevir, the,compan...ill be presented at,the 39th annual Digestive Dise...
(Date:5/15/2008)...ULOUSE, France, May 15 /- Cerenis,The...tical company,developing HDL-related compounds for...eases, today announced that it has completed a Pha...y,s lead product candidates.,CER-002 is a peroxiso...ecific agonist in development for the treatment of...
Breaking Medicine Technology:Eisai's Commitment to Oncology Demonstrated by Clinical Data to be Presented at ASCO Annual Meeting 2Eisai's Commitment to Oncology Demonstrated by Clinical Data to be Presented at ASCO Annual Meeting 3Eisai's Commitment to Oncology Demonstrated by Clinical Data to be Presented at ASCO Annual Meeting 4Eisai's Commitment to Oncology Demonstrated by Clinical Data to be Presented at ASCO Annual Meeting 5Eisai's Commitment to Oncology Demonstrated by Clinical Data to be Presented at ASCO Annual Meeting 6Eisai's Commitment to Oncology Demonstrated by Clinical Data to be Presented at ASCO Annual Meeting 7Eisai's Commitment to Oncology Demonstrated by Clinical Data to be Presented at ASCO Annual Meeting 8Poniard to Present Clinical Data From Picoplatin Trials in Multiple Tumor Types at American Society of Clinical Oncology 2008 Annual Meeting 2Poniard to Present Clinical Data From Picoplatin Trials in Multiple Tumor Types at American Society of Clinical Oncology 2008 Annual Meeting 3Poniard to Present Clinical Data From Picoplatin Trials in Multiple Tumor Types at American Society of Clinical Oncology 2008 Annual Meeting 4Poniard to Present Clinical Data From Picoplatin Trials in Multiple Tumor Types at American Society of Clinical Oncology 2008 Annual Meeting 5Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Hepatitis C Data Presentations at Digestive Disease Week (DDW) Annual Meeting 2Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Hepatitis C Data Presentations at Digestive Disease Week (DDW) Annual Meeting 3Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Hepatitis C Data Presentations at Digestive Disease Week (DDW) Annual Meeting 4Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Hepatitis C Data Presentations at Digestive Disease Week (DDW) Annual Meeting 5Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Hepatitis C Data Presentations at Digestive Disease Week (DDW) Annual Meeting 6Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Hepatitis C Data Presentations at Digestive Disease Week (DDW) Annual Meeting 7Cerenis Therapeutics Completes Phase I Clinical Trial of CER-002 for Treatment of Cardiovascular Disease 2Kaiser Permanente Study Shows Newer Stronger Evidence That Caffeine During Pregnancy Increases Miscarriage Risk 2671 1Kaiser Permanente Study Shows Newer Stronger Evidence That Caffeine During Pregnancy Increases Miscarriage Risk 2671 2Kaiser Permanente Study Shows Newer Stronger Evidence That Caffeine During Pregnancy Increases Miscarriage Risk 2671 3Kaiser Permanente Study Shows Newer Stronger Evidence That Caffeine During Pregnancy Increases Miscarriage Risk 2671 4Kaiser Permanente study shows link between caffeine and miscarriage 9813 1Kaiser Permanente study shows link between caffeine and miscarriage 9813 2Kaiser Permanente study shows link between caffeine and miscarriage 9813 3Pros cons of drug proven to prevent prostate cancer should be considered researchers recommend 9810 1Pros cons of drug proven to prevent prostate cancer should be considered researchers recommend 9810 2NEWSWEEK 3A Media Lead Sheet January 28 2008 Issue 28on newsstands Monday January 21 29 9809 1NEWSWEEK 3A Media Lead Sheet January 28 2008 Issue 28on newsstands Monday January 21 29 9809 2NEWSWEEK 3A Media Lead Sheet January 28 2008 Issue 28on newsstands Monday January 21 29 9809 3NEWSWEEK 3A Media Lead Sheet January 28 2008 Issue 28on newsstands Monday January 21 29 9809 4NEWSWEEK 3A Media Lead Sheet January 28 2008 Issue 28on newsstands Monday January 21 29 9809 5...wire/ -- Scientists,at WEHI have made a discovery ...e of patients, especially those undergoing,cancer ...min Kile and David Huang has,discovered that plate...The discovery raises the prospect of developing a ...red in blood banks,effectively increasing the ava...
...07 - A study comparing,the formulations of isosorb... V-HeFT I and V-HeFT II, and BiDil, the proprietar...ican Heart Failure,Trial (A-HeFT) demonstrated no ...ions used may explain why V-HeFT I and V-HeFT II,s...ty. Using,identical amounts of active drugs, the t...
Other Medicine Technology:Major Discovery Raises Prospect of Better Patient Care By Improving,Platelet Life Span 2Major Discovery Raises Prospect of Better Patient Care By Improving,Platelet Life Span 3Study: Identical Doses of BiDil Components Are Not Bioequivalent to,the Fixed Dose Combination-BiDil-Used in A-HeFT 2Study: Identical Doses of BiDil Components Are Not Bioequivalent to,the Fixed Dose Combination-BiDil-Used in A-HeFT 3Study: Identical Doses of BiDil Components Are Not Bioequivalent to,the Fixed Dose Combination-BiDil-Used in A-HeFT 4Study: Identical Doses of BiDil Components Are Not Bioequivalent to,the Fixed Dose Combination-BiDil-Used in A-HeFT 5The Mitek CuffTack sutureless fixation device offers superior fixation strength for rotator cuff repairs. The implant firmly reattaches soft tissue to the bone with one step insertion. CuffTack is in
...imple to use system can be used for open or arthro... a sterile disposable inserter. The unique deploym... insertion of the anchor into bone. The Independe...lows for the two pre-threaded sutures to independe...
The Micro Anchor is the smallest, strongest anchor on the market allowing exceptional flexibility in placement into even the smallest bones. This anchor comes pre-loaded with 3-0 or 4-0 ETHIBOND EXCE
FASTIN RC is a threaded titanium anchor, specifically designed for rotator cuff procedures. The anchor features wide threads and a small core to optimize bone purchase, as well as independent suture
Medicine Products: